NASDAQ : COAG
Hemab Therapeutics Holdings, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 41.29 USD (Oct 30, 2026, 3:42 PM EDT) · Market cap 1.93B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 14.74M | 10.49M | 8.97M |
| Research & Development | 72.45M | 59.63M | 41.41M |
| Operating Expenses | 87.19M | 70.12M | 50.38M |
| Operating Income | -87.19M | -70.12M | -50.38M |
| Interest & Investment Income | 5.24M | 1.97M | 3.74M |
| Other Non Operating Income (Expenses) | -317.00K | 4.00M | -1.88M |
| Pretax Income | -83.17M | -64.14M | -48.52M |
| Income Tax Expense | 68.00K | -227.00K | 185.00K |
| Net Income | -83.23M | -63.91M | -48.71M |
| Net Income to Common | -83.23M | -63.91M | -48.71M |
| Shares Outstanding (Basic) | 8.28M | 946.00K | 946.00K |
| Shares Outstanding (Diluted) | 8.28M | 946.00K | 946.00K |
| EPS (Basic) | -10.06 | -67.56 | -51.49 |
| EPS (Diluted) | -10.06 | -67.56 | -51.49 |
| Free Cash Flow | -77.47M | -61.49M | -45.87M |
| Free Cash Flow Per Share | -9.36 | -65.00 | -48.49 |
| EBITDA | -86.89M | -69.81M | -50.13M |
| D&A For EBITDA | 300.00K | 304.00K | 248.00K |
| EBIT | -87.19M | -70.12M | -50.38M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 237.37M | 87.97M | 74.41M |
| Short-Term Investments | 220.09M | 97.51M | 13.92M |
| Cash & Short-Term Investments | 457.46M | 185.49M | 88.33M |
| Other Receivables | 1.82M | 2.63M | 1.58M |
| Receivables | 1.82M | 2.63M | 1.58M |
| Prepaid Expenses | 4.72M | 4.44M | 3.33M |
| Total Current Assets | 464.00M | 192.55M | 93.23M |
| Property, Plant & Equipment | 1.50M | 1.70M | 2.57M |
| Other Long-Term Assets | 2.29M | 531.00K | 476.00K |
| Total Assets | 467.78M | 194.78M | 96.28M |
| Accounts Payable | 6.23M | 5.73M | 3.16M |
| Accrued Expenses | 5.26M | 3.96M | 2.46M |
| Current Portion of Leases | 460.00K | 693.00K | 789.00K |
| Other Current Liabilities | 990.00K | 294.00K | 274.00K |
| Total Current Liabilities | 12.94M | 10.68M | 6.68M |
| Long-Term Leases | 566.00K | 573.00K | 1.10M |
| Other Long-Term Liabilities | 17.00K | ||
| Total Liabilities | 13.51M | 11.25M | 7.80M |
| Common Stock | 5.00K | 132.00K | 132.00K |
| Additional Paid-In Capital | 685.71M | 4.92M | 2.90M |
| Retained Earnings | -228.69M | -181.86M | -117.94M |
| Comprehensive Income & Other | -2.75M | 175.00K | -365.00K |
| Total Common Equity | 454.27M | -176.63M | -115.27M |
| Shareholders' Equity | 454.27M | 183.53M | 88.47M |
| Total Liabilities & Equity | 467.78M | 194.78M | 96.28M |
| Total Debt | 1.03M | 1.27M | 1.89M |
| Net Cash (Debt) | 456.43M | 184.22M | 86.43M |
| Net Cash Per Share | 55.14 | 194.73 | 91.37 |
| Filing Date Shares Outstanding | 46.71M | 43.00K | 946.00K |
| Total Common Shares Outstanding | 46.71M | 43.00K | 946.00K |
| Working Capital | 451.05M | 181.87M | 86.55M |
| Book Value Per Share | 9.73 | -4,107.79 | -121.85 |
| Tangible Book Value | 454.27M | -176.63M | -115.27M |
| Tangible Book Value Per Share | 9.73 | -4,107.79 | -121.85 |
| Machinery | 1.39M | 1.25M | 1.23M |
| Leasehold Improvements | 82.00K | 82.00K | 82.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -83.23M | -63.91M | -48.71M |
| Depreciation & Amortization | 300.00K | 304.00K | 248.00K |
| Loss (Gain) From Sale of Investments | -2.57M | -768.00K | -1.28M |
| Stock-Based Compensation | 4.39M | 2.01M | 1.91M |
| Other Operating Activities | 476.00K | -464.00K | 794.00K |
| Change in Accounts Payable | 2.51M | 2.58M | 911.00K |
| Change in Other Net Operating Assets | 799.00K | -1.22M | 536.00K |
| Operating Cash Flow | -77.33M | -61.48M | -45.59M |
| Capital Expenditures | -135.00K | -16.00K | -282.00K |
| Investment in Securities | -220.14M | -81.47M | 62.19M |
| Investing Cash Flow | -220.27M | -81.48M | 61.90M |
| Long-Term Debt Repaid | -120.00K | -100.00K | |
| Net Debt Issued (Repaid) | -107.00K | -120.00K | -100.00K |
| Other Financing Activities | -477.00K | -477.00K | |
| Financing Cash Flow | 473.48M | 156.30M | -100.00K |
| Foreign Exchange Rate Adjustments | 1.00K | 223.00K | |
| Net Cash Flow | 175.88M | 13.57M | 16.21M |
| Free Cash Flow | -77.47M | -61.49M | -45.87M |
| Free Cash Flow Per Share | -9.36 | -65.00 | -48.49 |
| Levered Free Cash Flow | -39.59M | ||
| Unlevered Free Cash Flow | -39.59M | ||
| Cash Interest Paid | 3.00K | 10.00K | 18.00K |
| Cash Income Tax Paid | 172.00K | 88.00K | |
| Change in Working Capital | 3.31M | 1.35M | 1.45M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.91B | ||
| Enterprise Value | 1.46B | ||
| Debt / Equity Ratio | 0.00 | 0.01 | 0.02 |
| Net Debt / Equity Ratio | -1.00 | -1.00 | -0.98 |
| Net Debt / EBITDA Ratio | 5.25 | 2.64 | 1.72 |
| Net Debt / FCF Ratio | 5.89 | 3.00 | 1.88 |
| Quick Ratio | 35.48 | 17.62 | 13.45 |
| Current Ratio | 35.85 | 18.03 | 13.95 |
| Return on Equity (ROE) | -46.99% | ||
| Return on Assets (ROA) | -30.11% | ||
| Return on Capital Employed (ROCE) | -19.20% | -38.10% | -56.20% |